In direct compression lines operating at rotary press speeds from 40 to 60 rpm, the spray-dried liposomal alpha-lipoic acid (ALA) powder is handled as a low-moisture lipid matrix rather than as a free-flowing crystalline solid. The phospholipid envelope contributes plastic deformation under compaction; tablets therefore develop higher compact strength at moderate compression pressures between 100 and 160 MPa, but lamination can occur on the lower punch if the press lacks a precompression stage of 5–8 kN. Mean particle size of the API is commonly controlled between 75 µm and 180 µm for powder flow, and colloidal silicon dioxide is added at 0.5–1.0% w/w to suppress electrostatic charge on phospholipid surfaces. The direct compression matrix contains microcrystalline cellulose PH-102 at 40–60% w/w, anhydrous dibasic calcium phosphate at 20–30% w/w, crospovidone at 2–5% w/w, and magnesium stearate limited to 0.5–1.0% w/w because over-lubrication in a V-blender beyond 3 minutes at 25 rpm produces hydrophobic films that depress dissolution. Tablet hardness is maintained at 70–110 N for 10.0 mm round concave tooling, and disintegration is tested in 900 mL of purified water at 37 °C per USP <701>. Content uniformity follows USP <905>, and dissolution is evaluated per USP <711> Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer containing 0.5% w/w sodium dodecyl sulfate. Published data for direct compression of spray-dried liposomal ALA at production batch sizes is limited; process parameters are therefore transferred from lipid-based multivitamin formulations and verified on a compaction simulator before scale-up. Magnesium stearate contact time above 10 minutes is an operational boundary; the dissolution rate in the first 15 minutes can fall below the label-release specification if the lubricant coats the lipid matrix. Tablets should be protected against oxygen headspace in primary packaging because the lipid envelope is susceptible to peroxidation.

What Limits Dry Capsule Fill Weight Uniformity for Liposomal ALA Blends?

Dry capsule fill weight for liposomal ALA blends is governed less by API loss on drying than by static charging of phospholipid-coated particles on encapsulation line contact surfaces. Bulk density after spray drying may fall between 0.25 and 0.45 g/mL, and Carr compressibility index values above 25 are common when no glidant is used. On tamping pin encapsulators, dosing discs are selected so that the plug compression force remains between 10 and 25 N; at higher forces phospholipid components shear into films that line the disc bores and produce weight variation failures under USP <905>. Encapsulation rooms are maintained at 40% RH or lower; moisture uptake above this level plasticizes the lipid phase and creates a tacky fill that adheres to the dosing disc. Capsule shell selection operates as a second moisture barrier: gelatin shells with moisture content above 13–15% w/w transfer water into the fill, while HPMC shells with low moisture are preferred for long-term stability. The fill formulation normally contains croscarmellose sodium at 2–4% w/w as disintegrant, but this range is reduced if the blend is stored longer than 7 days because croscarmellose can absorb atmospheric moisture and promote lipid hydrolysis. Fill weight control is monitored at intervals of 5 minutes during the start-up phase and then every 15 minutes; a weight variation above 3.0% RSD indicates an electrostatic charge or disc bore coating event. Dissolution of capsules is run in USP <711> Apparatus I or II at 100 rpm and 50 rpm, respectively, with pH 6.8 dissolution medium containing 1.0% w/v sodium lauryl sulfate to ensure complete release of ALA from the lipid matrix.

When Wet Granulation Is Selected for Oral Granules, the Binder-To-Lipid Ratio Governs Redispersibility

Wet granulation of liposomal ALA requires a binder-to-lipid ratio that is high enough to consolidate fines but low enough to avoid lipid film formation during drying. In a high-shear granulator fitted with a 5 L bowl and chopper speed of 1500–2500 rpm, a PVP K30 binder solution at 5% w/w is sprayed onto a dry blend of liposomal ALA, mannitol, and pregelatinized starch. The endpoint is monitored by impeller power consumption; a power increase of 15–25% relative to the dry blend is typically used to stop binder addition. Wet mass moisture content is controlled between 10 and 14% w/w before extrusion through a 1.0 mm screen. Drying is carried out in a fluid bed at inlet air temperature not exceeding 50 °C, because higher temperatures accelerate phospholipid oxidation and produce a lipid odor. Loss on drying after drying should be 1.5–2.5% w/w for stick-pack granules; if moisture falls below 1.0% w/w, static charge increases and granule friability rises. Redispersion is tested by adding the granule mass to 20 mL of purified water at 25 °C in a 50 mL cylinder and inverting 10 times; a translucent dispersion should form within 2 minutes. If HPMC E3 is substituted at 2.0–4.0% w/w, disintegration is slightly slower but less sticky on drying screens than PVP. Binder levels above 5.0% w/w produce a film-like granule surface that delays water penetration and leaves visible lipid aggregates after the suspension is left unstirred for 5 minutes. This scenario is particularly relevant for sachet products reconstituted in water or soft food before oral administration, where incomplete dispersion changes the dose delivered in the first portion.

Lyophilization of liposomal ALA for parenteral administration is a process of two coupled constraints: the liposome must survive freezing without vesicle fusion, and the cake must reconstitute to a particle size population compatible with intravenous administration. The aqueous bulk is prepared by hydrating a phospholipid/ALA matrix in a high-shear mixer or rotor-stator at 10,000–20,000 rpm for 10–20 minutes, followed by size reduction in a high-pressure homogenizer or microfluidizer-type equipment operating at 10,000–25,000 psi. Sucrose or trehalose is added to the aqueous phase at a saccharide-to-phospholipid mass ratio between 2:1 and 5:1; below 2:1 cryoprotection is insufficient and vesicle fusion is observed as a bimodal size distribution after reconstitution, while above 5:1 the product may exceed isotonicity limits and require dilution. The aqueous phase pH is adjusted to 6.0–7.0 with sodium hydroxide or a sodium phosphate buffer of 10–25 mM to balance ALA carboxylate solubility and phospholipid hydrolysis. Osmolality is checked with a freezing point osmometer and adjusted to 250–350 mOsm/kg using sodium chloride or mannitol; mannitol can crystallize during freezing, so amorphous sucrose is preferred in formulations where liposome integrity must be preserved through annealing. Freezing is performed at shelf temperature -40 °C for 120 minutes, followed by annealing at -20 °C for 60 minutes to allow solute phase separation and reduce primary drying resistance. Primary drying is run at shelf temperature -30 to -20 °C with chamber pressure 50–90 mTorr until the product temperature probe records a plateau and the Pirani/capacitance pressure differential approaches zero. Secondary drying is performed at 20–25 °C for 6–12 hours; residual moisture by Karl Fischer per USP <921> Method Ia is typically below 2.0% w/w. Cakes with residual moisture above 3.0% w/w often show collapsed or shrinkage structure because amorphous sucrose absorbs moisture during storage. Reconstitution with water for injection to the original fill volume should disperse the cake within 30 seconds under gentle swirling; visible aggregates after 2 minutes indicate either freeze-damage or moisture ingress. Full release testing includes USP <71> sterility and USP <85> bacterial endotoxins.

Injectable Liposome Sterile Filtration and Particulate Matter Thresholds

Sterile filtration of liposomal ALA injection product demands a filter train that does not strip the lipid phase. A prefilter of 0.45 µm followed by a sterilizing-grade 0.22 µm membrane is used for a bulk mean particle size below 200 nm z-average. Dynamic light scattering per ISO 22412:2017 is recorded before and after filtration; a shift in z-average larger than 20–30 nm after filtration is interpreted as filter-induced aggregation. Filter material is typically polyethersulfone or PVDF; nylon membranes are avoided because they may adsorb phospholipid aggregates. Filter compatibility studies are run with the actual bulk at 2–8 °C and at room temperature for a minimum of 2 hours to detect pressure build-up. Subvisible particulate matter is tested on the finished vial per USP <788> Method 1; for small-volume containers, the accepted limits are 6000 particles per container ≥ 10 µm and 600 particles per container ≥ 25 µm. For liposomes, a focused beam light obscuration measurement after stress testing is necessary because liposomal vesicles themselves can contribute to the 10 µm channel if aggregation occurs. Visible particulates are inspected per USP <790> as a 100% in-process check; any visible particle above the acceptance threshold triggers a reject of the affected fill segment. Vial headspace is purged with nitrogen before stoppering to limit oxidative degradation during terminal processing.

At pH Values Below 5.5, Liposomal ALA Aqueous Dispersions Enter an Aggregation Regime

At pH values below 5.5, liposomal ALA aqueous dispersions begin to lose colloidal stability because the carboxyl group of alpha-lipoic acid shifts toward the unionized form, reducing surface charge on phospholipid bilayers. This condition also accelerates hydrolysis of phosphatidylcholine to lysophosphatidylcholine and free fatty acids; the degradation products are surface-active and can promote membrane fusion. Release criteria for lysophosphatidylcholine in bulk solution are often set below 1.0% of total phospholipid mass for liquid injectable products. Above pH 7.5, alpha-lipoic acid undergoes ring-opening and disulfide polymerization reactions that increase solution color and generate high-molecular-weight impurities. Thus liquid injectable formulations are maintained within 6.0–7.0, with nitrogen overlay in the vial headspace to keep dissolved oxygen below 0.5 mg/L before sealing. Aluminum crimp seals with chlorobutyl rubber stoppers are preferred; silicone tubing transfer lines should be pre-treated because lipophilic adsorption to silicone can remove as much as 10–15% of the lipid dose during filling if not flushed with product bulk. For terminal sterilization of liposomal ALA, steam cycles above 121 °C are contraindicated for unsaturated lipids; even for saturated phospholipid systems the increase in free fatty acids and loss of encapsulated drug can exceed release limits. Aseptic filtration at 0.22 µm remains the default route; if terminal sterilization is claimed, the sterilization cycle and lipid hydrolysis profile must be supported by data meeting the requirements of ICH Q1A(R2) and EU GMP Annex 1.